MedPath

Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain

Not Applicable
Conditions
Cancer Pain
Interventions
Other: mini program
Other: conventional pharmaceutical care
First Posted Date
2021-04-14
Last Posted Date
2021-04-14
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
200
Registration Number
NCT04844645

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

First Posted Date
2021-03-08
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
1600
Registration Number
NCT04785768
Locations
🇨🇳

China, Fujian, Fuzhou, Fujian, China

Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study

Phase 2
Conditions
Advanced Colorectal Cancer
Interventions
Drug: Surufatinib
First Posted Date
2021-02-21
Last Posted Date
2021-11-04
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
10
Registration Number
NCT04764006
Locations
🇨🇳

China, Fujian, Fuzhou, Fujian, China

Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC

Conditions
Nasopharyngeal Carcinoma
Interventions
Radiation: IB-positive group
First Posted Date
2021-02-09
Last Posted Date
2021-04-29
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
200
Registration Number
NCT04745741
Locations
🇨🇳

Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Phase 2
Conditions
Advanced Colorectal Cancer
Interventions
Drug: Surufatinib(HMPL-012)
First Posted Date
2021-02-02
Last Posted Date
2021-02-02
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
56
Registration Number
NCT04734249

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Phase 2
Conditions
NSCLC Stage IV
Interventions
Drug: Toripalimab Injection
First Posted Date
2020-11-03
Last Posted Date
2020-11-03
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
30
Registration Number
NCT04613804
Locations
🇨🇳

Fujian cancer hospital, Fuzhou, Fujian, China

Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain

Phase 3
Conditions
Opioid, Moderate Cancer Pain, Transdermal Fentanyl, 12.5ug/h, Opioid-naive
Interventions
Drug: 2.5ug/h transdermal fentanyl
Drug: Oral immediate-released morphine
First Posted Date
2020-08-31
Last Posted Date
2020-08-31
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
209
Registration Number
NCT04533243

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Phase 2
Conditions
Nasopharyngeal Carcinoma
Interventions
Drug: Triprilimab(JS001)
First Posted Date
2020-06-09
Last Posted Date
2020-06-09
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
39
Registration Number
NCT04421469
Locations
🇨🇳

Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC

Completed
Conditions
Nasopharyngeal Carcinoma
Interventions
Radiation: modified reduce-volume target IMRT
First Posted Date
2020-05-13
Last Posted Date
2020-10-09
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
471
Registration Number
NCT04387266
Locations
🇨🇳

Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Phase 2
Recruiting
Conditions
Pulmonary Adenosquamous Carcinoma
Interventions
Drug: Almonertinib
First Posted Date
2020-04-21
Last Posted Date
2023-11-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
13
Registration Number
NCT04354961
Locations
🇨🇳

Beijing Chest Hospital, Capital Medical University, Beijing, China

🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

and more 15 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy